Showing results (711-720 of 727) with videos related to
Sort By:
Pageof 73
The American Journal of Gastroenterology|July 30, 2025
Measuring the Risk of Gluten Exposure: Development of the Gluten Exposure Risk Assessment (GERA) in Pediatric PatientsAmy E Hale, Monique Germone, Lisa Fahey, et al.Bioorganic & Medicinal Chemistry Letters|August 17, 2005
A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cellsMark W Embrey, John S Wai, Timothy W Funk, et al.Antimicrobial Agents and Chemotherapy|December 3, 1998
ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseH L Sham, D J Kempf, A Molla, et al.Applied and Environmental Microbiology|November 18, 2018
Diversity in CO2-Concentrating Mechanisms among Chemolithoautotrophs from the Genera Hydrogenovibrio, Thiomicrorhabdus, and Thiomicrospira, Ubiquitous in Sulfidic Habitats WorldwideKathleen M Scott, Juliana M Leonard, Rich Boden, et al.Journal of Medicinal Chemistry|April 2, 2005
9-hydroxyazafluorenes and their use in thrombin inhibitorsKenneth J Stauffer, Peter D Williams, Harold G Selnick, et al.AIDS Research and Human Retroviruses|April 20, 2000
Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infectionM L Markert, C B Hicks, J A Bartlett, et al.Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonistsMichael R Wood, Kathy M Schirripa, June J Kim, et al.Science Advances|October 9, 2020
Hemispherical differences in the shape and topography of asteroid (101955) BennuM G Daly, O S Barnouin, J A Seabrook, et al.Journal of Medicinal Chemistry|February 7, 2003
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridinesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.Pageof 73